Welcome to our dedicated page for Shockwave Medical news (Ticker: $SWAV), a resource for investors and traders seeking the latest updates and insights on Shockwave Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shockwave Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shockwave Medical's position in the market.
Rhea-AI Summary
Shockwave Medical, Inc. (NASDAQ: SWAV) to participate in Piper Sandler 35th Annual Healthcare Conference. Management scheduled for a live fireside chat on November 29, 2023, at 1:30 p.m. Eastern Time. Webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary
Shockwave Medical, Inc. (NASDAQ: SWAV) Announces Excellent One-Year Outcomes with Coronary IVL Published in JSCAI, Demonstrating Consistent Safety and Effectiveness Across Sexes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
-
Rhea-AI Summary
Shockwave Medical, Inc. (Nasdaq: SWAV) reported a 42% increase in revenue for the third quarter of 2023, reaching $186.0 million. The company also raised $634.4 million in a convertible debt offering. They introduced the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter and received a Category I CPT add-on code for procedures involving coronary IVL, which will provide physicians with a 20-30% increase in remuneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.08%
Tags
Rhea-AI Summary
Shockwave Medical announced the establishment of a new CPT® add-on code for procedures involving coronary Intravascular Lithotripsy (IVL) as part of the Calendar Year 2024 Physician Fee Schedule. The new code, +92972, will become effective on January 1, 2024, and will provide additional work Relative Value Units (RVUs) and professional fees for physicians. This code will be added to the remuneration physicians receive for percutaneous coronary intervention (PCI) procedures, including when atherectomy is also performed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
Rhea-AI Summary
Shockwave Medical, Inc. will report financial results for the third quarter 2023 after market close on November 6, 2023. Company management will host a conference call and present at the 5th Annual Wolfe Research Healthcare Conference on November 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
-
Rhea-AI Summary
Shockwave Medical announces the planned U.S. introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter following FDA approval. The enhanced C2+ catheter provides 50% more pulses per catheter than the previous version. The full commercial launch is planned for November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
Rhea-AI Summary
Shockwave Medical announces excellent outcomes with coronary intravascular lithotripsy (IVL) in complex nodular and eccentric calcium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary
Shockwave Medical, Inc. to host Investor Innovation Day on October 23, 2023, in hybrid format.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Nick West joins Shockwave as Associate Chief Medical Officer. His expertise in interventional cardiology will support the development of Intravascular Lithotripsy (IVL) as the standard of care for calcium modification. He also brings experience in evaluating and developing novel technologies. Dr. West was previously Chief Medical Officer at Abbott Vascular. His knowledge in intravascular imaging will benefit Shockwave IVL customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
Rhea-AI Summary
Shockwave Medical's CFO, Dan Puckett, plans to retire in Q1 2024. The company is searching for a successor. Puckett will continue as CFO until then. Puckett's efforts contributed to successful funding rounds and a successful IPO. No concrete positive or negative impacts on stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
Shockwave Medical, Inc.
Nasdaq:SWAV
SWAV Rankings
SWAV Stock Data
12.39B
36.82M
1.27%
95.6%
5.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SANTA CLARA
About SWAV
shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen